• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特罗特单抗相关皮肤超敏反应。

Teprotumumab-related Cutaneous Hypersensitivity Reactions.

机构信息

Division of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, Shiley Eye Institute, UC San Diego, La Jolla, CA, U.S.A.

Division of Pediatric Ophthalmology and Adult Strabismus, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, CA, U.S.A.

出版信息

Ophthalmic Plast Reconstr Surg. 2023;39(6):e208-e210. doi: 10.1097/IOP.0000000000002482. Epub 2023 Sep 1.

DOI:10.1097/IOP.0000000000002482
PMID:37656913
Abstract

The authors report 4 cases of cutaneous hypersensitivity reactions developing in the course of teprotumumab treatment for thyroid eye disease. The onset of the cutaneous hypersensitivity reaction was also observed during the treatment course in all cases, between the second and fifth infusions. Teprotumumab-related cutaneous reactions suggest a possible immunogenic component of the monoclonal antibody and highlight the importance of close monitoring during treatment.

摘要

作者报告了 4 例在使用替普妥单抗治疗甲状腺眼病过程中出现的皮肤过敏反应。所有病例均在第二次至第五次输注期间观察到皮肤过敏反应的发生。与替普妥单抗相关的皮肤反应提示该单克隆抗体可能具有免疫原性成分,并强调了在治疗期间密切监测的重要性。

相似文献

1
Teprotumumab-related Cutaneous Hypersensitivity Reactions.特罗特单抗相关皮肤超敏反应。
Ophthalmic Plast Reconstr Surg. 2023;39(6):e208-e210. doi: 10.1097/IOP.0000000000002482. Epub 2023 Sep 1.
2
Teprotumumab for the treatment of thyroid eye disease.特普替尼单抗治疗甲状腺眼病。
Expert Rev Clin Immunol. 2020 Aug;16(8):739-743. doi: 10.1080/1744666X.2020.1801421. Epub 2020 Aug 9.
3
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.替普罗单抗治疗活动性甲状腺眼病患者:两项随机、双盲、安慰剂对照、多中心试验的汇总数据分析、亚组分析及停药后随访结果
Lancet Diabetes Endocrinol. 2021 Jun;9(6):360-372. doi: 10.1016/S2213-8587(21)00056-5. Epub 2021 Apr 15.
4
Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.甲状腺眼病、替普罗单抗与听力损失:耳鼻喉科医生的角色演变
Otolaryngol Head Neck Surg. 2021 Dec;165(6):757-758. doi: 10.1177/01945998211004240. Epub 2021 Mar 30.
5
Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease.替罗非班治疗甲状腺眼病患者的枪伤致听力损失加重。
Ophthalmic Plast Reconstr Surg. 2022;38(2):e41-e43. doi: 10.1097/IOP.0000000000002078.
6
Teprotumumab: First Approval.特罗替珠单抗:首次获批
Drugs. 2020 Apr;80(5):509-512. doi: 10.1007/s40265-020-01287-y.
7
Teprotumumab for the Treatment of Active Thyroid Eye Disease.特罗特鲁单抗治疗活动性甲状腺眼病。
N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434.
8
Ototoxicity and Teprotumumab.耳毒性和特罗曲珠单抗。
Ann Otol Rhinol Laryngol. 2022 Aug;131(8):910-913. doi: 10.1177/00034894211042740. Epub 2021 Aug 27.
9
Teprotumumab-Induced Encephalopathy: A Rare Side Effect of a Novel Therapeutic.特罗替珠单抗相关性脑病:一种新型治疗药物的罕见不良反应。
WMJ. 2023 May;122(2):134-137.
10
Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.使用半剂量疗法降低替普罗单抗诱导的听力损失且疗效相当
Ophthalmic Plast Reconstr Surg. 2023;39(4):e101-e104. doi: 10.1097/IOP.0000000000002355. Epub 2023 Mar 3.

引用本文的文献

1
Thyroid Eye Disease: Advancements in Orbital and Ocular Pathology Management.甲状腺眼病:眼眶及眼部病理学管理的进展
J Pers Med. 2024 Jul 22;14(7):776. doi: 10.3390/jpm14070776.